CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Frexalimab’s Role in Immune Modulation and MS Pathogenesis
In a meticulous phase 2 trial, researchers have embarked on evaluating the efficacy of frexalimab, a second-generation anti-CD40L monoclonal antibody, in the treatment of relapsing multiple sclerosis. This study stands out for its potential to redefine therapeutic strategies against a backdrop of immune system regulation, spotlighting the CD40–CD40L costimulatory pathway’s pivotal role in the disease’s pathogenesis.
Study Design:
- Participants: 129 individuals with relapsing multiple sclerosis were randomly assigned in a 4:4:1:1 ratio to different treatment groups.
- Treatment Regimens: Participants received either 1200 mg of frexalimab intravenously every 4 weeks (plus an 1800-mg loading dose) or 300 mg subcutaneously every 2 weeks (plus a 600-mg loading dose), against matching placebos.
- Duration and Follow-up: The primary endpoint was assessed at week 12, with all participants eligible for open-label frexalimab post the double-blind period.
Key Findings:
- Efficacy: Frexalimab showed a significant reduction in new gadolinium-enhancing T1-weighted lesions at week 12, with adjusted mean numbers of 0.2 and 0.3 for intravenous and subcutaneous administrations, respectively, versus 1.4 in the placebo group.
- Safety Profile: The most common adverse events reported were COVID-19 and headaches.
- Implications for Treatment: These results hint at frexalimab’s potential as a promising treatment avenue for multiple sclerosis, warranting further large-scale and long-term studies.
HCN Medical Memo
In this phase 2 trial, frexalimab’s inhibition of CD40L significantly reduced new gadolinium-enhancing T1-weighted lesions in multiple sclerosis patients, indicating the need for extended studies to confirm its long-term efficacy and safety.
More on Multiple Sclerosis (MS)
